Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis). Issue 8 (8th June 2022)

• Record Type: Journal Article
• Authors: Malagoli, Piergiorgio; Dapavo, Paolo; Pavia, Giulia; Amoruso, Fabrizio; Argenziano, Giuseppe; Bardazzi, Federico; Burlando, Martina; Carrera, Carlo G.; Damiani, Giovanni; Dini, Valentina; Girolomoni, Giampiero; Guarneri, Claudio; Loconsole, Francesco; Narcisi, Alessandra; Sampogna, Francesca; Travaglini, Massimo; Costanzo, Antonio
• Is Part Of: Dermatologic therapy. Volume 35:Issue 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-08
• Subjects: ixekizumab -- long‐term efficacy -- real‐life experience; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15608
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate‐to‐severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL‐17A with high specificity and affinity. Inhibiting IL‐17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long‐term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate‐to‐severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow‐up of care until 192 weeks.